CanSinoBIO's Convidecia Air™ Approved for Emergency Use in Morocco
2022-11

Tianjin, November 10, 2022 - CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today
announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation
(trade name: Convidecia Air™) has been approved for emergency use by the Ministre de la Sante et de
la Protection Sociale (Maroc), Morocco's Ministry of Health and Social Protection, representing the first
overseas approval of Convidecia Air™.


Convidecia Air™, utilizing Aerogen's proprietary aerosol drug delivery technology, has so far been
approved for emergency use in China and Morocco. It is the world's first approved inhaled COVID-19
vaccine, based on the same adenovirus vector technological platform of CanSinoBIO's Convidecia™
administered via intramuscular injection.


Peer-reviewed research1 shows that Convidecia Air™ is safe to use with only one-fifth of the dosage of
the intramuscular version of CanSinoBIO's COVID-19 vaccine. By using Convidecia Air™ as a
heterologous booster, it generated much stronger immune responses than those induced by a
homologous inactivated vaccine booster2. The inhaled treatment can achieve triple protection as it
triggers a mucosal immune response in addition to humoral and cellular immunity observed in people
who were vaccinated with the intramuscular version.


Currently, Convidecia Air™ has been rolled out in China, including Shanghai, Tianjin, and Jiangsu
province, to help strengthen protection for the Chinese population against COVID-19 and its variants
with a more efficient delivery method which is needle-free, painless and non-invasive.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Cansino Biologics Inc. published this content on 10 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2022 01:21:23 UTC.